Home/Pipeline/Undisclosed Heart Regeneration Program

Undisclosed Heart Regeneration Program

Heart Failure

Pre-clinicalActive

Key Facts

Indication

Heart Failure

Phase

Pre-clinical

Status

Active

Company

Animatus Biosciences

About Animatus Biosciences

Animatus Biosciences is pioneering a novel approach to regenerative medicine for heart failure, a leading cause of death with a $60B+ annual US treatment cost. The company's platform centers on a proprietary 'regenerative cocktail' of synthetic factors intended to stimulate the replication of adult heart cells (cardiomyocytes), which are normally unable to regenerate. This direct in vivo repair strategy seeks to address the root cause of heart failure—irreversible cell loss—rather than just managing symptoms. If successful, it could transform treatment for millions of patients currently dependent on limited options like heart transplants.

View full company profile

Therapeutic Areas

Cardiovascular Disease Heart Failure

Other Heart Failure Drugs

Drug	Company	Phase	Status
Cardiac Cell Therapy Program	StemCardia	Pre-clinical	Active
NTP42	ATXA Therapeutics	Preclinical	Platform potential identified
Heart Failure Trial	Clinical Investigation Specialists	Not Specified	Actively Recruiting
INPEFA (sotagliflozin)	Lexicon Pharmaceuticals	Approved	Commercial
MyCardia™	Avery Therapeutics	Pre-clinical	Active
Cardiac Assist Device	Second Heart Assist	Pre-clinical	Active
Isosorbide Dinitrate/Hydralazine HCl Tablets	i3 Pharmaceuticals	Approved	Active
TLT-101	TikkunLev Therapeutics	Pre-clinical	Active
AFteR Registry	Occlutech	N/A (Registry)	Active
biotx.ai Target Discovery Collaboration	HeartBeat.bio	Pre-clinical	Active
Surlorian	RyCarma Therapeutics	Phase 2	Active
Coronary Sinus Reduction	Shockwave Medical	Unknown	Active